Dendritic Cell Cancer Vaccines Market

Dendritic Cell and Tumor Cell Cancer Vaccines Market, 2016-2030

  • Lowest Price Guaranteed From USD 2,349

  • Companies Covered
    260

  • Pages
    314

  • View Count
    10066

Dendritic Cell Cancer Vaccines Market Overview

The global dendritic cell cancer vaccines market is expected to reach $3.2 billion by 2030, growing at an annualized rate of over 20.7%. Cancer is an extremely complex disease and medical science is still trying to understand the numerous factors responsible for its origin, propagation, spread (metastasis) and relapse. In 2016, an estimated 1.7 million new cancer cases were reported in the US alone. Furthermore, as projected by the World Health Organization (WHO), the annual incidence of cancer worldwide is expected to rise to 24 million by 2035. Currently, there is a huge unmet need for advanced and efficient treatment interventions for cancer. Standard approaches that are currently employed to treat cancer include surgery, radiation therapy and chemotherapy. Although all the three approaches are recognized as the current standard of care in cancer treatment, there are some risks and drawbacks associated with these methods.

Many pharmaceutical companies are working on identifying ways to improve these treatment methods, as well as develop new cancer therapies. One of the current focus areas is immunotherapy; it makes use of the body’s own immune system, or its components, to fight cancer. So far, antibody based therapeutics, including monoclonal antibodies (mAbs), bispecific antibodies (bsAbs) and antibody drug conjugates (ADCs), have had significant success as targeted anti-cancer therapies. Apart from antibody based therapies, there are other classes of immunotherapeutics that have been / are being developed to manage and treat cancer; these include immune checkpoint inhibitors (ICIs), therapeutic cancer vaccines and other whole cell based therapies.

The USFDA has approved cancer prevention vaccines (the human papillomavirus (HPV) vaccine andhepatitis B vaccine (HBV)) that prevent infection with cancer-causing viruses. Gardasil, Gardasil 9 and Cervarix are approved for the prevention of HPV-caused cancers whereas Engerix-B, Recombivax HB, Twinrix and Pediarix are approved for the prevention of chronic HBV infection. Although, preventive vaccines offer several benefits, the fact that viruses do not cause most cancers cannot be overlooked. Therefore, several companies are developing therapeutic vaccines that target specific cancers.

As of now, there are three marketed therapeutic cancer vaccines commercially available in different geographies; these include PROVENGE (US), CreaVax-RCC (South Korea) and TAPCells (Chile). Despite the limited success of PROVENGE, the first marketed dendritic cancer vaccine, several stakeholders are actively engaged in the development of dendritic cancer vaccine. Additionally, in August 2020, Elios Therapeutics developed a personalized vaccine for high-risk melanoma patients that improves long-term survival.

Recent Developments in Dendritic Cell Cancer Vaccines Market:

Several recent developments have taken place in the field of dendritic cell cancer vaccines market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In September 2023, Moderna entered into a strategic partnership with Immatics with an aim to enable the discovery and development of novel mRNA-based cancer vaccines. 
  • In August 2023, Moderna collaborated with CARsgen in order to develop combined Car-T cancer vaccine.

Scope of the Report

The "Dendritic Cell Cancer Vaccines Market, 2016-2030" market report offers a comprehensive analysis of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the dendritic cell cancer vaccines market. Currently, there are five types of such vaccines; these are dendritic cell vaccines, tumor cell vaccines, antigen / peptide vaccines, DNA vaccines and anti-idiotypic vaccines. This market research report is focused on the recent developments and the future potential of dendritic cell vaccines (dendritic cell loaded vaccines) and tumor cell vaccines (tumor cell loaded vaccines).  

During the course of our market report, we identified a variety of dendritic cell and tumor cell cancer vaccines across various stages of development. More than 75% of these product candidates are currently in the clinical stages of development. With a rich development pipeline, this segment of the immunotherapy market has managed to capture the interest of several strategic investors and venture capital firms. During our research, we observed that over USD 1.5 billion has already been invested in dendritic cell cancer vaccines market in past five years. Owing to the existing unmet demand for safe and effective cancer therapies and given the innate advantages of immunotherapies, we believe that dendritic cancer vaccine present lucrative opportunities for both therapy developers and investors alike.

One of the key objectives of the market report was to understand the primary growth drivers and estimate the future size of the dendritic cell cancer vaccines market. For this purpose, we took into consideration the following parameters:

  • The dendritic cell and tumor cell vaccines pipeline, including marketed, clinical and preclinical therapies, in terms of phase of development, key players, type of donor and target indications.
  • The existing and emerging technology platforms used for the development of innovative variants of cancer vaccines.
  • The partnerships that have taken place in the recent past covering clinical trial collaborations, research collaborations, manufacturing and services agreements, license agreements specific to technology platforms and agreements related to the co-development and co-commercialization of promising candidates.
  • Various investments and grants received by companies focused in this area including capital raised from IPOs and subsequent offerings.
  • The performance of competing drug classes, complex manufacturing processes, batch-wise variability and other inherent threats to growth of the market in the short and long term.

The key objective of dendritic cell cancer vaccines market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for dendritic cell cancer vaccines market during the forecast period. This opportunity is linked to the target consumer segments, likely adoption rate and expected pricing. We have provided an estimate of the size of the market in the short-mid-term and long term for the forecast period between 2016 and 2030. The base year for the market research report is 2016. To account for the uncertainties associated with the development of novel therapeutic classes and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base, and optimistic tracks of the market’s evolution.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com